ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes through transdermal patch technology, today announced the addition of two experienced professionals to its management and Board. Dr. Julian Howell joins the Company as Chief Medical Advisor and Nitin Kaushal joins the Company’s Board of Directors.
“We are pleased to welcome Julian and Nitin to our team, and believe their experience will be invaluable to the company in its rapid development pace,” said Pedro Lichtinger, Chairman and CEO. “Their experience in clinical development and in financing will support our low risk, fast to market, and limited capital needs strategy. Julian and Nitin have strong track records as trusted leaders in the biotech industry and I look forward to working with them.”
“I am very pleased to be joining the ChemioCare team as the company is preparing to take products in to clinical development,” stated Dr. Howell. “I look forward to bringing my experience in supportive care specifically to assist the Company as we develop differentiated products to improve CINV control for patients.”
“I am excited to join ChemioCare’s Board of Directors,” said Mr. Kaushal. “This is a unique opportunity to help shape a Company with de-risked products targeting markets with significant unmet medical needs.”
Julian Howell, MBBS, FRCS, FFPM, MBA
Dr. Julian Howell, MBBS, FRCS, FFPM, MBA, has broad experience in development of CINV products; including successful registration and launch of Sancuso® (granisetron patch) and Kytril® (granisetron oral). Clinical development experience spanning 15 years, bringing small molecules and biological products through all phases of clinical development including multiple product approvals in Europe and the US. He gained medical and surgical qualifications in the UK and worked in the UK health service before completing an MBA at Cranfield University and joining the pharmaceutical industry, initially at SmithKlineBeecham and subsequently in senior clinical and medical affairs roles at Roche, Chiron and Pharmion.
Nitin Kaushal
Nitin Kaushal is a Managing Director in the Deals practice at PwC Canada. Nitin has more than 25 years experience in the financial investing, life sciences, consumer health care, health care services and medical device industries. His experience includes board of directorships with pharmaceutical and health care companies. He has also held senior roles in investment banking, venture capital and consulting firms. Nitin has performed over 50 merger, acquisition, strategic advisory, and licensing assignments. He has been an advisor to many of the leading global pharma companies and has participated in capital market transactions raising in excess of $2Bn.
About ChemioCare
A biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes through transdermal patch technology. ChemioCare has 4 single active ingredient patches in development using proprietary, proven transdermal patch technology. The company is targeting the 505(b)2 regulatory path with key differentiators on-label, establishing improved efficacy and reduced or eliminated side effects from originator products.
To learn more, visit www.chemio.care
This press release contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of the business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as “may,” “should,” “plan,” “intend,” “potential,” “continue,” “believe,” “expect,” “predict,” “anticipate” and “estimate,” the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside the company’s control, involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on the company’s beliefs, assumptions and expectations of future performance, taking into account information currently available to the company. Neither the company, nor any other person assumes responsibility for the accuracy or completeness of these statements. Information in this press release will be updated only to the extent required under applicable laws. If a change occurs, business, financial condition, liquidity and results of operations may vary materially for from those expressed in the aforementioned forward-looking statements.
